Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis (2017)

  • Authors:
  • USP affiliated authors: ANNICHINI, MARIA SOL BRASSESCO - FFCLRP ; MACHADO, HÉLIO RUBENS - FMRP ; SERAFINI, LUCIANO NEDER - FMRP ; SCRIDELI, CARLOS ALBERTO - FMRP ; TONE, LUIZ GONZAGA - FMRP
  • USP Schools: FFCLRP; FMRP; FMRP; FMRP; FMRP
  • DOI: 10.1007/s00381-017-3366-5
  • Subjects: MEDULOBLASTOMA; INIBIDORES DE ENZIMAS
  • Keywords: MEDULLOBLASTOMA; PLKS; MIR-100; MIR-126; MIR-217; MIR-593
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s00381-017-3366-5 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    Versões disponíveis em Acesso Aberto do: 10.1007/s00381-017-3366-5 (Fonte: Unpaywall API)

    Título do periódico: Child's Nervous System

    ISSN: 0256-7040,1433-0350



      Não possui versão em Acesso aberto

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      PEZUK, Julia Alejandra; BRASSESCO, Maria Sol; OLIVEIRA, Ricardo Santos de; et al. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis. Child's Nervous System, Berlin, v. 33, n. 4, p. 609–615, 2017. DOI: 10.1007/s00381-017-3366-5.
    • APA

      Pezuk, J. A., Brassesco, M. S., Oliveira, R. S. de, Machado, H. R., Neder, L., Scrideli, C. A., & Tone, L. G. (2017). PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis. Child's Nervous System, 33( 4), 609–615. doi:10.1007/s00381-017-3366-5
    • NLM

      Pezuk JA, Brassesco MS, Oliveira RS de, Machado HR, Neder L, Scrideli CA, Tone LG. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis. Child's Nervous System. 2017 ; 33( 4): 609–615.
    • Vancouver

      Pezuk JA, Brassesco MS, Oliveira RS de, Machado HR, Neder L, Scrideli CA, Tone LG. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis. Child's Nervous System. 2017 ; 33( 4): 609–615.

    Referências citadas na obra
    Bihannic L, Ayrault O (2016) Insights into cerebellar development and medulloblastoma. Bull Cancer 103:30–40. doi: 10.1016/j.bulcan.2015.11.002
    Sadighi Z, Vats T, Khatua S (2012) Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile. J Child Neurol 27:1302–1307. doi: 10.1177/0883073812449690
    Kijima N, Kanemura Y (2016) Molecular classification of medulloblastoma. Neurol Med Chir (Tokyo). doi: 10.2176/nmc.ra.2016-0016
    Crawford JR, MacDonald TJ, Packer RJ (2007) Medulloblastoma in childhood: new biological advances. Lancet Neurol 6:1073–1085. doi: 10.1016/S1474-4422(07)70289-2
    Remke M, Ramaswamy V, Taylor MD (2013) Medulloblastoma molecular dissection: the way toward targeted therapy. Curr Opin Oncol 25:674–681. doi: 10.1097/CCO.0000000000000008
    Vaid R, Sharma N, Chauhan S et al (2016) Functions of polo-like kinases: a journey from yeast to humans. Protein Pept Lett 23:185–197
    Johnson EF, Stewart KD, Woods KW et al (2007) Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 46:9551–9563. doi: 10.1021/bi7008745
    De Falco M, De Luca A (2010) Cell cycle as a target of antineoplastic drugs. Curr Pharm Des 16:1417–1426
    Palmisiano ND, Kasner MT (2015) Polo-like kinase and its inhibitors: ready for the match to start? Am J Hematol 90:1071–1076. doi: 10.1002/ajh.24177
    Pezuk JA, Brassesco MS, Morales AG et al (2013) Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation. Cancer Biother Radiopharm 28:516–522. doi: 10.1089/cbr.2012.1415
    de Oliveira JC, Brassesco MS, Pezuk JA et al (2012) In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. J Drugs Dermatol 11:587–592
    Liu Z, Sun Q, Wang X (2017) PLK1, a potential target for cancer therapy. Transl Oncol 10:22–32. doi: 10.1016/j.tranon.2016.10.003
    Harris PS, Venkataraman S, Alimova I et al (2012) Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 12:80. doi: 10.1186/1471-2407-12-80
    Guerreiro AS, Fattet S, Kulesza DW et al (2011) A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res 9:925–935. doi: 10.1158/1541-7786.MCR-10-0200
    Winkles JA, Alberts GF (2005) Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24:260–266. doi: 10.1038/sj.onc.1208219
    Petrelli A, Perra A, Schernhuber K et al (2012) Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 31:4517–4526. doi: 10.1038/onc.2011.631
    Ito T, Sato F, Kan T et al (2011) Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer. Int J Cancer 129:2134–2146. doi: 10.1002/ijc.25874
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408. doi: 10.1006/meth.2001.1262
    Taylor MD, Northcott PA, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465–472. doi: 10.1007/s00401-011-0922-z
    Degenhardt Y, Lampkin T (2010) Targeting polo-like kinase in cancer therapy. Clin Cancer Res 16:384–389. doi: 10.1158/1078-0432.CCR-09-1380
    Guan R, Tapang P, Leverson JD et al (2005) Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65:2698–2704. doi: 10.1158/0008-5472.CAN-04-2131
    Pellegrino R, Calvisi DF, Ladu S et al (2010) Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 51:857–868. doi: 10.1002/hep.23467
    Schmit TL, Ledesma MC, Ahmad N (2010) Modulating polo-like kinase 1 as a means for cancer chemoprevention. Pharm Res 27:989–998. doi: 10.1007/s11095-010-0051-8
    Triscott J, Lee C, Foster C et al (2013) Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children. Cancer Res 73:6734–6744. doi: 10.1158/0008-5472.CAN-12-4331
    Ou B, Zhao J, Guan S et al (2016) Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/cyclin E in colorectal cancer. Cancer Lett 380:457–466. doi: 10.1016/j.canlet.2016.07.004
    Cizmecioglu O, Warnke S, Arnold M et al (2008) Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain. Cell Cycle 7:3548–3555
    Archambault V, Glover DM (2009) Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10:265–275. doi: 10.1038/nrm2653
    Yang Y, Bai J, Shen R et al (2008) Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 68:4077–4085. doi: 10.1158/0008-5472.CAN-07-6182
    Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643–660. doi: 10.1038/nrd3184
    de Cárcer G, Escobar B, Higuero AM et al (2011a) Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol 31:1225–1239. doi: 10.1128/MCB.00607-10
    de Cárcer G, Manning G, Malumbres M (2011b) From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 10:2255–2262. doi: 10.4161/cc.10.14.16494
    Voorhoeve PM, Agami R (2007) Classifying microRNAs in cancer: the good, the bad and the ugly. Biochim Biophys Acta - Rev Cancer 1775:274–282. doi: 10.1016/j.bbcan.2006.11.003
    Kozomara A, Griffiths-Jones S (2014) MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42:68–73. doi: 10.1093/nar/gkt1181
    Chou C-H, Chang N-W, Shrestha S et al (2016) miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44:D239–D247. doi: 10.1093/nar/gkv1258
    Sarachana T, Zhou R, Chen G, et al (2010) Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profi ling of lymphoblastoid cell lines.
    Shi W, Alajez NM, Bastianutto C et al (2010) Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer 126:2036–2048. doi: 10.1002/ijc.24880
    Zhao L-L, Jin F, Ye X et al (2015) Expression profiles of miRNAs and involvement of miR-100 and miR-34 in regulation of cell cycle arrest in Artemia. Biochem J 470:223–231. doi: 10.1042/BJ20150116
    Li BH, Zhou JS, Ye F et al (2011) Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur J Cancer 47:2166–2174. doi: 10.1016/j.ejca.2011.04.037
    Li Z, Lu J, Sun M et al (2008) Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 105:15535–15540. doi: 10.1073/pnas.0808266105
    Ishizaki T, Tamiya T, Taniguchi K et al (2011) miR126 positively regulates mast cell proliferation and cytokine production through suppressing Spred1. Genes Cells 16:803–814. doi: 10.1111/j.1365-2443.2011.01529.x
    Yang S, Li Y, Gao J et al (2013) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 32:4294–4303. doi: 10.1038/onc.2012.432
    Crawford M, Brawner E, Batte K et al (2008) MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373:607–612. doi: 10.1016/j.bbrc.2008.06.090